CPT code 87801 denotes a molecular laboratory test that detects multiple infectious agents using an amplified nucleic acid probe technique. Nationally, such multiplex molecular assays are important for rapid and specific identification of pathogens, supporting public health surveillance, infection control, and targeted clinical management. The code covers testing performed in clinical and hospital laboratory settings where amplified probe methods are used to simultaneously assess more than one infectious agent.

Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise summary of the clinical context for multiplex amplified probe testing, benchmark considerations for coverage and reimbursement across major payers, and notes on typical site-of-service delivery. The publication outlines coding and billing considerations relevant to laboratory administrators and billing professionals, including common modifiers when applicable and service-line placement.

The content provides actionable clarity on what CPT code 87801 represents, why multiplex amplified nucleic acid probe testing matters nationally, and what stakeholders should expect in terms of payer coverage patterns and clinical utility. Data not available in the input is noted where relevant.